Profile data is unavailable for this security.
About the company
INIFY Laboratories AB is a Sweden-based medical research company that provides cancer diagnostics through laboratory services within pathology. The Company uses a fully digital, standardized and Artificial Intelligence (AI)- supported workflow to optimize quality and response times, initially within prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. INIFY Laboratories' laboratory in Solna, Sweden is intended to provide two types of analyses of prostate Biopsy Specimens to clients: Full pathology Report signed by an INIFY subspecialized pathologist and Whole Slide Images (WSI) generation and result of Pathology Decision Support Tool (PDST) analysis only. The Company origins from ContextVision.
- Revenue in NOK (TTM)3.41m
- Net income in NOK-51.23m
- Incorporated2021
- Employees23.00
- LocationINIFY Laboratories ABScheeles vag 3SOLNA 171 65SwedenSWE
- Phone+46 8267330
- Websitehttps://www.inify.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lytix Biopharma AS | 3.99m | -87.94m | 277.82m | -- | -- | 4.43 | -- | 69.61 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.037 | -- | 0.4091 | -- | -81.63 | -57.34 | -94.30 | -66.09 | -- | -- | -2,203.36 | -4,665.04 | -- | -- | -- | -- | 183.25 | 63.94 | -57.01 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -215.13m | 296.40m | 5.00 | -- | 1.45 | -- | -- | -6.54 | -6.54 | 0.00 | 4.95 | 0.00 | -- | -- | 0.00 | -116.46 | -125.17 | -130.53 | -151.70 | -- | -- | -- | -- | -- | -- | 0.0036 | -- | -- | -- | -117.54 | -- | -- | -- |
| Xbrane Biopharma AB | 190.37m | -360.14m | 307.99m | 75.00 | -- | 0.7839 | -- | 1.62 | -1.33 | -1.58 | 0.6978 | 0.2577 | 0.2465 | 1.34 | 332.12 | 2,053,430.00 | -46.63 | -40.98 | -78.01 | -67.24 | 15.43 | -- | -189.18 | -364.40 | 1.43 | -31.13 | 0.3693 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Ascelia Pharma AB | 0.00 | -108.95m | 312.29m | 13.00 | -- | 4.35 | -- | -- | -3.20 | -3.20 | 0.00 | 2.13 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -85.53 | -- | -- | -- | -- | -- | -- | -- | 0.0141 | -- | -- | -- | 16.72 | -- | -- | -- |
| Herantis Pharma Oyj | 0.00 | 3.25m | 327.74m | 10.00 | 111.38 | 5.97 | 100.86 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
| Intervacc AB | 7.99m | -102.53m | 328.42m | 15.00 | -- | 1.38 | -- | 41.10 | -1.47 | -1.47 | 0.1167 | 3.14 | 0.0306 | 3.08 | 1.72 | 534,333.30 | -39.21 | -17.62 | -42.12 | -18.77 | -628.60 | -243.59 | -1,283.24 | -626.90 | 4.38 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Medivir AB | 7.71m | -96.22m | 333.99m | 10.00 | -- | 1.58 | -- | 43.33 | -1.46 | -1.46 | 0.1028 | 1.89 | 0.032 | -- | 1.56 | 773,300.00 | -40.00 | -28.91 | -47.20 | -34.77 | -888.81 | -467.42 | -1,248.18 | -675.96 | -- | -- | 0.0482 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| Magle Chemoswed Holding AB | 169.48m | 12.19m | 346.67m | 78.00 | 28.44 | 2.15 | 13.88 | 2.05 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| Lifecare ASA | 13.09m | -35.26m | 417.41m | 32.00 | -- | 6.29 | -- | 31.90 | -0.2903 | -0.2903 | 0.1088 | 0.4924 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| INIFY Laboratories AB | 3.41m | -51.23m | 425.66m | 23.00 | -- | 5.84 | -- | 124.90 | -1.13 | -1.13 | 0.0753 | 1.61 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -101.30m | 448.80m | 30.00 | -- | 0.5475 | -- | -- | -0.2554 | -0.2554 | 0.00 | 0.8165 | 0.00 | -- | -- | 0.00 | -14.77 | -18.84 | -15.78 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0325 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -35.58m | 474.78m | 2.00 | -- | 27.12 | -- | -- | -0.6567 | -0.6567 | 0.00 | 0.3319 | 0.00 | -- | -- | 0.00 | -58.55 | -65.10 | -62.50 | -70.59 | -- | -- | -- | -- | -- | -- | 0.5804 | -- | -- | -- | 40.52 | -- | -- | -- |
| Promimic AB | 36.95m | -9.19m | 483.57m | 17.00 | -- | 6.32 | -- | 13.09 | -0.5283 | -0.5283 | 2.08 | 4.11 | 0.3994 | -5.63 | 3.00 | 2,180,588.00 | -9.93 | -24.89 | -11.67 | -29.25 | 103.90 | 101.23 | -24.88 | -89.47 | 3.98 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Bergenbio ASA | 354.00k | -190.40m | 510.48m | 18.00 | -- | 2.75 | -- | 1,442.03 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Enzymatica AB (publ) | 47.14m | -53.50m | 547.90m | 18.00 | -- | 6.55 | -- | 11.62 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Hamlet BioPharma AB | 0.00 | -26.51m | 571.87m | 7.00 | -- | 12.67 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
Data as of May 16 2024. Currency figures normalised to INIFY Laboratories AB's reporting currency: Norwegian Krone NOK
8.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management Sweden)as of 01 Feb 2024 | 2.05m | 4.53% |
| MP Pensjon PKas of 01 Feb 2024 | 1.37m | 3.03% |
| SEB Investment Management ABas of 01 Feb 2024 | 185.44k | 0.41% |
| Aktia Fondbolag Abas of 30 Apr 2024 | 172.70k | 0.38% |
More ▼
Data from 31 Mar 2024 - 15 May 2024Source: FactSet Research Systems Inc.
